Viking Therapeutics (VKTX) has moved deeper into late stage obesity drug development, completing enrollment in its Phase 3 VANQUISH-1 and VANQUISH-2 trials for injectable VK2735 and outlining plans for an oral Phase 3 program.

The wider Q1 loss, as R&D spending ramped for Phase 3 obesity programs, appears to be weighing on sentiment in the short term, with a 1 month share price return decline of 8.98% and a year to date share price return decline of 15.30%, even as the 5 year total shareholder return is very large.

If you are comparing Viking with other obesity and metabolic names, it can help to widen the lens using a healthcare focused AI stock screener such as 33 healthcare AI stocks

With Viking’s shares giving back ground in recent months despite full Phase 3 enrollment and a very large 5 year return, the key question now is simple: is the current price a reset that creates an entry point, or is the market already looking ahead and factoring in potential future growth?

Most Popular Narrative: 67.6% Undervalued

Viking Therapeutics last closed at $30, while the most followed narrative assigns a fair value of $92.72, creating a wide gap for investors to weigh.

Parallel development of subcutaneous and oral formulations of the same GLP 1 and GIP co agonist, including plans to start Phase III oral trials and an oral maintenance strategy, directly responds to rising patient interest in flexible obesity treatment options and could support broader market reach and future earnings growth.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that valuation gap? The narrative focuses on future revenue, margin expansion and a lofty earnings multiple. Curious which assumptions really move the fair value number?

Result: Fair Value of $92.72 (UNDERVALUED)

However, the story can change quickly if the VANQUISH Phase 3 trials disappoint, or if heavy R&D spend and any future equity raises dilute your exposure.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to look at the full picture for yourself and decide quickly how you feel about Viking. To weigh both sides of the argument in one place, start with the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss out on other opportunities that better match your goals, time horizon, and comfort with risk.

• Target dependable income by scanning companies with stronger yields and staying power using the 13 dividend fortresses.
• Spot potential value candidates before the crowd by working through the screener containing 25 high quality undiscovered gems.
• Prioritize resilience and capital protection by filtering for companies with steadier profiles through the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.